复发/难治性弥漫大B细胞淋巴瘤的结局及二线嵌合抗原受体T细胞试验入组标准的影响:一项基于人群的736例患者研究
该研究基于瑞典2007-2014年736例复发/难治性弥漫大B细胞淋巴瘤患者,评估生存及与疾病特征、二线治疗和符合嵌合抗原受体T细胞试验标准的关系。中位总生存6.6个月,早期复发与选择低强度治疗和生存差强相关。即使符合CAR T试验标准的患者预后也差,为新颖疗法疗效提供基准。
要点
- 中位总生存为6.6个月(≤70岁9.6个月,>70岁4.9个月)。
- ≤70岁患者中63%开始强化二线治疗,34%接受自体干细胞移植。
- 移植患者2年总生存56%(早期复发≤12个月40%,晚期复发>12个月66%)。
核心结论
- 大多数复发/难治性弥漫大B细胞淋巴瘤表现为早期复发,常不适合或无法完成强化方案,导致生存极差。
- 符合CAR T试验标准的真实世界患者预后也差,为新颖疗法疗效提供基准。
研究设计与样本
- 基于人群研究,纳入瑞典2007-2014年所有接受治愈性治疗的弥漫大B细胞淋巴瘤患者中736例复发/难治性患者。
- 评估生存及与疾病特征、二线治疗和符合嵌合抗原受体T细胞试验标准的关系。
主要发现
- 中位总生存6.6个月(≤70岁9.6个月,>70岁4.9个月)。
- 早期复发(≤12个月)与选择低强度治疗和生存差强相关。
- ≤70岁患者中63%开始强化二线治疗,34%接受自体干细胞移植。
- 移植患者2年总生存56%(早期复发≤12个月40%,晚期复发>12个月66%)。
- 少数患者(35%,178/506)符合CAR T试验标准;早期复发且符合标准者中位无进展生存4.8个月。
关键数值与推荐
- 中位总生存:总体6.6个月,≤70岁9.6个月,>70岁4.9个月。
- ≤70岁患者强化二线治疗启动率63%,自体干细胞移植率34%。
- 移植患者2年总生存56%(早期复发≤12个月40%,晚期复发>12个月66%)。
- 符合CAR T试验标准比例35%(178/506);早期复发且符合标准者中位无进展生存4.8个月。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Several recently published trials investigate novel therapies for relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). To estimate the benefit of these therapies in the real-world setting, comprehensive data on patients treated in clinical routine are needed. We report outcomes for 736 R/R DLBCL patients identified among all curatively treated DLBCL patients in Sweden in the period 2007-2014. Survival and associations with disease characteristics, second-line treatment and fulfilment of chimaeric antigen receptor (CAR) T-cell trial criteria were assessed. Median overall survival (OS) was 6.6 months (≤70 years 9.6 months, >70 years 4.9 months). Early relapse (≤12 months) was strongly associated with selection of less intensive treatment and poor survival. Among patients of at most 70 years of age, 63% started intensive second-line treatment and 34% received autologous stem cell transplantation (ASCT). Two-year OS among transplanted patients was 56% (early relapse ≤12 months 40%, late relapse >12 months 66%). A minority of patients 76 years (n = 178/506, 35%) fitted CAR T trial criteria. Median progression-free survival (PFS) for patients with early relapse fitting trial criteria was 4.8 months. In conclusion, most R/R DLBCL manifest early and are often ineligible for or cannot complete intensive regimens resulting in dismal survival. Real-world patients eligible for CAR T trials also did poorly, providing a benchmark for efficacy of novel therapies.
引用
- Harrysson S, Eloranta S, Ekberg S, et al. Outcomes of relapsed/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line-A population-based study of 736 patients. Br J Haematol. 2022. PMID: 35468219. doi:10.1111/bjh.18197
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。